A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)

• ClinicalTrials.gov Identifier: NCT03355157
• Recruitment Status: Recruiting
• First Posted: November 28, 2017
• Last Update Posted: February 12, 2021
• Sponsor: German Breast Group
• Collaborators: Pfizer; AMS Advanced Medical Services GmbH
• Information provided by (Responsible Party): German Breast Group

Study Description

Brief Summary:

The goal of the study for patients with metastatic breast cancer (MBC) is to show that palbociclib + endocrine therapy shows a significant improvement in time-to-treatment failure over chemotherapy regimen (mono-chemotherapy with or without endocrine therapy). This would provide level 1 evidence from real world that palbociclib plus endocrine therapy is the first choice in MBC patients needing first-line therapy not only compared to endocrine therapy but also compared to chemotherapy with or without endocrine maintenance therapy.

In addition, we assume that patient-reported outcome as measured by FACT-B and a novel composite endpoint of well-being and healthcare utilization (DMTI) will be improved with palbociclib + endocrine treatment vs. chemotherapy regimen.

Condition or disease	Intervention/treatment	Phase
Metastatic Breast Cancer	Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 150 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
• Actual Study Start Date: March 1, 2018
• Estimated Primary Completion Date: March 31, 2023
• Estimated Study Completion Date: March 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Palbociclib + endocrine therapy; Experimental arm for testing palbociclib + endocrine therapy.	Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen); Drug intervention
Active Comparator: Chemotherapy +/- endocrine maintenance therapy; Chemotherapy +/- endocrine maintenance as comparator arm.	Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen); Drug intervention

Outcome Measures

Primary Outcome Measures :

1. Time-to-treatment failure (TTF) [ Time Frame: 31 months ]
   To compare the time-to-treatment failure (TTF) for patients randomized to receive pre-defined chemotherapy treatment strategy versus those randomized to receive palbociclib and endocrine therapy.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, willingness and ability to complete collection of data via wearable device and study mobile must be obtained and documented according to the local regulatory requirements.
2. Female or male patients.
3. Age ≥ 18 years old.
4. Metastatic invasive hormone receptor positive and HER2 negative breast cancer (histologically confirmed).
5. Patients who in the opinion of the treating physician are candidates suitable for randomization for mono-chemotherapy treatment, that has either an approved label in Europe and/or is supported by guidelines for the treatment of first-line advanced BC, which are based on evidence on safety and efficacy in this setting.
6. Symptomatic or asymptomatic metastatic breast cancer.
7. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
8. Life-expectancy > 6 months.
9. For female patients: The patients need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) B) childbearing potential with negative serum or urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive methods).

Exclusion Criteria:

1. Indication for poly-chemotherapy or single-agent endocrine therapy only or bevacizumab.
2. Asymptomatic oligometastases of the bone as the only site of metastatic disease.
3. Uncontrolled/untreated central nervous system lesions.
4. Patients who received treatment for metastatic/relapsed breast cancer.
5. Inadequate organ function as per physician's assessment immediate prior to randomization.
6. Treatment with preparations containing St. John´s Wort within the last 7 days prior to randomization and/or concurrent use.
7. Known severe hypersensitivity reactions to compounds or excipients similar to palbociclib, planned chemotherapy or planned endocrine therapy.
8. Existing contraindication against the use of palbociclib, planned chemotherapy or planned endocrine therapy.
9. Patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency, and glucose-galactose malabsorption.
10. Female patients: pregnancy or lactation at the time of randomization or intention to become pregnant during the study and up to six months after treatment. Male patients: Intention to beget a child during the study and up to six months after treatment.

Contacts and Locations

Contacts

Contact: Konstantin Reißmüller; 49-6102-7480 ext 438; konstantin.reissmueller@gbg.de

Locations

Germany

Agaplesion Markus Krankenhaus - Klinik für Gynäkologie und Geburtshilfe; Recruiting

Frankfurt am Main, Germany, 60431

Contact: Marc Thill, MD, PhD marc.thill@fdk.info

Sponsors and Collaborators

German Breast Group

Pfizer

AMS Advanced Medical Services GmbH

Investigators

• Study Chair: Sibylle Loibl, MD, PhD; German Breast Group - GBG Forschungs GmbH

More Information

• Responsible Party: German Breast Group
• ClinicalTrials.gov Identifier: NCT03355157
• Other Study ID Numbers: GBG 93; 2016-004482-89 ( EudraCT Number )
• First Posted: November 28, 2017
• Last Update Posted: February 12, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by German Breast Group:

Palbociclib; Endocrine Therapy; Chemotherapy; Real world setting; Electronic patient-reported outcome; Daily Monitoring Treatment Impact; Health care utilization (call tracking, geofencing)

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Tamoxifen; Paclitaxel; Vinorelbine; Capecitabine; Letrozole; Epirubicin; Fulvestrant; Palbociclib; Exemestane; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antibiotics, Antineoplastic